1. Signaling Pathways
  2. Immunology/Inflammation
  3. Toll-like Receptor (TLR)
  4. TLR7 Isoform

TLR7

 

TLR7 Related Products (39):

Cat. No. Product Name Effect Purity
  • HY-13740
    Resiquimod
    Agonist 99.95%
    Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
  • HY-B1370
    Hydroxychloroquine sulfate
    Inhibitor 99.99%
    Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling.
  • HY-B0180
    Imiquimod
    Agonist 99.96%
    Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist.
  • HY-B0180A
    Imiquimod hydrochloride
    Agonist 99.80%
    Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist.
  • HY-109104
    Telratolimod
    Agonist 99.04%
    Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.
  • HY-145961
    TLR7 agonist 4
    Agonist 98.87%
    TLR7 agonist 4 (Compound 1.2) is a TLR7 agonist with an EC50 of 4.3 nM.
  • HY-150158
    TMX-201
    TMX-201 is a TLR7 ligand-phospholipid conjugate.
  • HY-145960
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4
    Agonist 99.39%
    MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate.
  • HY-134581
    Enpatoran
    Inhibitor 99.77%
    Enpatoran (M5049) is a potent, orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively.
  • HY-134581A
    Enpatoran hydrochloride
    Inhibitor 98.82%
    Enpatoran (M5049) hydrochloride is a potent, orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively.
  • HY-124603
    AT791
    Inhibitor 98.77%
    AT791 is a potent and orally bioavailable TLR7 and TLR9 inhibitor.
  • HY-110120
    DSR-6434
    Agonist 98.33%
    DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC50s of 7.2 nM and 4.6 nM for human and mice TLR7, respectively.
  • HY-118250
    GSK2245035
    Agonist 99.79%
    GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties.
  • HY-103697A
    Gardiquimod diTFA
    Agonist 99.77%
    Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist.
  • HY-111786
    LHC-165
    Agonist 98.17%
    LHC-165 is a TLR7 agonist.
  • HY-115400
    1V209
    Agonist 99.59%
    1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects.
  • HY-130797
    TLR7/8 agonist 3
    Agonist 99.02%
    TLR7/8 agonist 3 is a potent TLR7 and TLR8 agonist, extracted from patent WO2016057618 (compound of formula (II)).
  • HY-135905
    CL264
    Inhibitor 98.63%
    CL264 is a TLR7-specific agonist for innate immune signals research.
  • HY-139323
    TLR7/8-IN-1
    Inhibitor 99.80%
    TLR7/8-IN-1 is a crystalline from of a TLR7/TLR8 inhibitor extracted from patent WO2019220390, compound 2b.
  • HY-131945
    CU-115
    Antagonist 98.10%
    CU-115 is a potent TLR8 antagonist (IC50=1.04 µM), and shows selective for TLR8 over TLR7 (IC50=>50 µM).